Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Paediatrics
  4. Back
  5. Respiratory (Paediatric)
  6. Eradication of Pseudomonas Aeruginosa in Children with Cystic Fibrosis, Paediatrics (702)
Important: please update your RDS app to version 4.7.3 Details with newsletter below.

Please update your RDS app to v4.7.3

We asked you in January to update to v4.7.2.  After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. 

To update to the latest release:

 On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Right Decision Service newsletter: February 2025

Welcome to the February 2025 update from the RDS team

1.     Next release of RDS

 

A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:

 

  • Fixes to mitigate the recurring glitches with the RDS admin area and the occasional brief user interface outages which have arisen following implementation of the new distributed technology infrastructure in December 2024.

 

  • Capability to embed content from Google calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream into RDS pages.

 

  • Capability to include simple multiplication in RDS calculators.

 

The release will also incorporate a number of small fixes, including:

  • Exporting of form within Medicines Sick Day Guidance in polypharmacy toolkit
  • Links to redundant content appearing in search in some RDS toolkits
  • Inclusion of accordion headers alongside accordion text in search result snippets.
  • Feedback form on mobile app.
  • Internal links on mobile app version of benzo tapering tool

 

We will let you know when the date and time for the new release are confirmed.

 

2.     New RDS developments

There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.

The Benzodiazepine tapering tool (https://rightdecisions.scot.nhs.uk/benzotapering) is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.

3.     Archiving and version control and new RDS Search and Browse interface

Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.

4.     Statistics

At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .

 

5.     Review of content past its review date

We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.

 

6.     Toolkits in development

Some important toolkits in development by the RDS team include:

  • National CVD prevention pathways – due for release end of March 2025.
  • National respiratory pathways, optimal cancer diagnostic pathways and cancer prehabilitation pathways from the Centre for Sustainable Delivery. We will shortly start work on the national cancer referral pathways, first version due for release via RDS around end of June 2025.
  • HIS Quality of Care Review toolkit – currently in final stages of quality assurance.

 

The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.

 

7. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 28th February 12-1 pm
  • Tuesday 11th March 4-5 pm

 

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

Eradication of Pseudomonas Aeruginosa in Children with Cystic Fibrosis, Paediatrics (702)

Disclaimer:
The following guideline has been developed for use within the Royal Hospital for Children, NHS Greater Glasgow and Clyde (NHSGGC). The guideline has been developed in collaboration with key stakeholders within NHSGGC, including Microbiology, Cystic Fibrosis, Infectious Disease and Pharmacy teams. The guideline has been approved by the Paediatric Antimicrobial Management Team and ratified by the NHSGGC Antimicrobial Utilisation Committee. The guideline does not account for epidemiology and resistance patterns outside of NHS GGC and use outside of the designated organisation is at the individual’s risk. 

Background

Pseudomonas aeruginosa is recognized as being a significant respiratory pathogen for patients who have Cystic Fibrosis (CF). Chronic colonisation with Pseudomonas aeruginosa is associated with poorer clinical outcome and attempted eradication on first culture is aimed at preventing this.1

Recommendation: When P. aeruginosa grows from respiratory culture for the first time (or where there is growth in a patient that has been clear of the organism for 6 months or more) eradication should be attempted.2

Please note: if Ps aeruginosa is resistant to Ciprofloxacin please seek Consultant Microbiologist advice.

MANAGEMENT OF A NEW CULTURE OF PSEUDOMONAS AERUGINOSA - GENERAL

CF MICROBIOLOGY STATUS AND SECOND-LINE ANTIBIOTIC

QtC Prolongation

There is a risk of QtC prolongation in patients commenced on ciprofloxacin. Baseline +/- repeat ECGs are recommended for all children with a cardiac history or where ciprofloxacin is used in combination with other QtC prolonging drugs. Common agents include: domperidone, metoclopramide, azithromycin, ondansetron, azole antifungals. For further information contact Pharmacy.

NEW CULTURE OF PSEUDOMONAS AERUGINOSA ORAL+ NEBULISED ERADICATION GUIDELINE

NEW CULTURE OF PSEUDOMONAS AERUGINOSA WITH RESPIRATORY EXACERBATION IV ANTIBIOTIC ERADICATION

EVALUATION PLAN

ANNUAL AUDIT OF:

  • NEW AND RECURRENT PSEUDOMONAS RATES
  • PSEUDOMONAS SUCCESSFUL ERADICATION RATES
  • Compliance with guidance for stopping pseudomonas eradication therapy

Editorial Information

Last reviewed: 22/02/2022

Next review date: 22/02/2024

Author(s): Dr Jane Wilkinson.

Version: 2

Approved By: Antimicrobial Utilisation Committee

Document Id: 702

References
  1. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonisation with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function cystic fibrosis. Pediatr Pulmonol 1997; 23:330- 335.
  2. Pseudomonas aeruginosa infection in people with cystic fibrosis. Suggestions for Prevention and Infection Control. CF Trust 2004 (updated Nov 2016)
  3. Clinical Guidelines: Care of Children with Cystic Fibrosis 2020; Royal Brompton and Harefield Hospitals.
  4. N. Høiby , B. Frederiksen T. Pressler. Eradication of early Pseudomonas aeruginosa infection. Department of Clinical Microbiology 9301, Rigshospitalet, University of Copenhagen, Juliane Maries Vej 22, 2100 Copenhagen, Denmark. Danish Cystic Fibrosis Center, Rigshospitalet, Copenhagen, Denmark
  5. EPIC Study 2012 
  6. Ana C. Blanchard, Eric Horton, Sanja Stanojevic, Louise Taylor, Valerie Waters, Felix Ratjen. Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis. Journal of Cystic Fibrosis 16 (2017) 395–400
  7. BNFC- Drug information, accessed via https://bnfc.nice.org.uk/ 03/11/2021
  8. Tobramycin (Inhaled) monograph – Paediatric; Children’s Antimicrobial Management Program (ChAMP); Perth Children’s Hospital; Oct 2019.